Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for G1 Therapeutics (GTHX : NSDQ)
 
 • Company Description   
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC.

Number of Employees: 148

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.27 Daily Weekly Monthly
20 Day Moving Average: 1,021,819 shares
Shares Outstanding: 42.71 (millions)
Market Capitalization: $225.06 (millions)
Beta: 2.03
52 Week High: $24.12
52 Week Low: $4.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.27% -10.20%
12 Week -51.92% -47.13%
Year To Date -48.38% -36.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
700 Park Offices Drive Suite 200
-
Research Triangle Park,NC 27709
USA
ph: 919-213-9835
fax: 919-741-5830
jmacdonald@g1therapeutics.com http://www.g1therapeutics.com
 
 • General Corporate Information   
Officers
John E. Bailey, Jr. - President; Chief Executive Officer and Director
Jennifer K. Moses - Chief Financial Officer
Willie A. Deese - Director
Glenn P. Muir - Director
Garry A. Nicholson - Director

Peer Information
G1 Therapeutics (CORR.)
G1 Therapeutics (RSPI)
G1 Therapeutics (CGXP)
G1 Therapeutics (BGEN)
G1 Therapeutics (GTBP)
G1 Therapeutics (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 3621LQ109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 42.71
Most Recent Split Date: (:1)
Beta: 2.03
Market Capitalization: $225.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.86 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.25
Price/Cash Flow: -
Price / Sales: 9.32
EPS Growth
vs. Year Ago Period: -76.92%
vs. Previous Quarter: -22.34%
Sales Growth
vs. Year Ago Period: -51.46%
vs. Previous Quarter: 19.08%
ROE
03/31/22 - -107.75
12/31/21 - -76.03
09/30/21 - -65.66
ROA
03/31/22 - -68.95
12/31/21 - -54.80
09/30/21 - -50.57
Current Ratio
03/31/22 - 5.96
12/31/21 - 8.82
09/30/21 - 8.68
Quick Ratio
03/31/22 - 5.73
12/31/21 - 8.69
09/30/21 - 8.63
Operating Margin
03/31/22 - -708.20
12/31/21 - -471.32
09/30/21 - -316.58
Net Margin
03/31/22 - -708.20
12/31/21 - -471.32
09/30/21 - -316.58
Pre-Tax Margin
03/31/22 - -704.95
12/31/21 - -468.38
09/30/21 - -313.84
Book Value
03/31/22 - 2.34
12/31/21 - 3.38
09/30/21 - 4.19
Inventory Turnover
03/31/22 - 0.69
12/31/21 - 1.05
09/30/21 - 1.56
Debt-to-Equity
03/31/22 - 0.76
12/31/21 - 0.52
09/30/21 - 0.17
Debt-to-Capital
03/31/22 - 43.03
12/31/21 - 34.38
09/30/21 - 14.51
 

Powered by Zacks Investment Research ©